DEXMEDETOMIDINE INJ,SOLN
Clinical Criteria Summary
Indications & Inclusion Criteria
- Patient must be receiving continuous respiratory monitoring and cardiac monitoring while receiving dexmedetomidine.
- Short-term sedation anticipated (<24 hours) as an alternative to propofol.
- Intermediate-term sedation (e.g., 24-72 hours) as an alternative to propofol or benzodiazepines where avoidance is desired.
- Transitioning from another sedative agent to facilitate ventilator weaning; may be continued during and post-extubation (typically 24-48 hours).
Exclusion Criteria
- Advanced heart block.
- Baseline bradycardia (e.g., <50 bpm).
- Known hypersensitivity.
- Concurrent use of or anticipated need for neuromuscular blockade where dexmedetomidine would be the sole sedative agent used.
- Active myocardial ischemia.
- Severe hypotension (e.g., systolic blood pressure <90 mmHg with the use of 2 or more vasopressors).
Dosage & Administration
- FDA approved dosing: Optional loading dose of 1 mcg/kg over 10 min (commonly omitted in ICU setting due to potential for hypotension and/or bradycardia) followed by a continuous infusion of 0.4 mcg/kg/hr, titrated to desired level of sedation (usual range 0.2-0.7 mcg/kg/hr), for up to 24 hours.
- Additional dosing: Omission, reduction, or slower infusions of the loading dose have been studied/observed. Maintenance doses up to 1.4 mcg/kg/hour (most patients requiring ≤1 mcg/kg/hr) and longer infusion durations (~3-5 days) used in clinical trials. Use beyond 24 hours associated with withdrawal symptoms, tolerance, tachyphylaxis, and dose-related increase in adverse reactions.
- Special Populations: Dose reductions should be considered in the elderly and in patients with hepatic impairment.
Monitoring Requirements
- Administration restricted to personnel privileged to provide care in ICU/intensive-care level, procedural, or operating room settings.
- Continuous respiratory and cardiac monitoring recommended (e.g., heart rate, pulse oximetry).
- Monitor for loss of oropharyngeal muscle tone resulting in airway obstruction in nonintubated patients.
- Monitor for clinically significant bradycardia, hypotension, and sinus arrest requiring intervention (dose reduction, discontinuation, fluids, pressors, or anticholinergic agents).
- Routinely evaluate patient’s level and need for sedation using a validated assessment tool.
- Routinely assess for pain and treat when needed (analgesic properties are not primary use).
Clinical Considerations & Special Populations
- Withdrawal: Potential withdrawal syndrome similar to clonidine if administered >24 hours. ~5% experience symptoms within 24 hours of discontinuation after up to 7 days use. Commonly reported: nausea, vomiting, agitation; hypertension and tachycardia also reported.
- Hemodynamic Risks: Reduces sympathetic nervous system activity. Use with caution in states where bradycardia/hypotension risk is pronounced (severe ventricular dysfunction, hypovolemia, advanced age, diabetes, chronic hypertension, significant aortic stenosis or left ventricular outflow tract obstruction).
- Serious CNS Pathology: Limited data for trauma, acute stroke, active seizures. Lacks anti-seizure activity. Consider potential for hypotension impacting cerebral hemodynamics when maintaining arterial blood pressure is critical.
- Drug Interactions: Additive effects may occur with co-administration of anesthetics, sedatives, hypnotics, opioids, negative chronotropic agents, and vasodilators.
- Adjunctive Treatment of Alcohol Withdrawal: Evidence limited to small RCTs/observational studies. May have benzodiazepine-sparing properties but unclear effect on intubation rates/duration or LOS. Should not be used alone (lacks antiseizure activity/effectiveness for delirium tremens). Case-by-case basis.
- ICU Delirium: Evidence limited/inconsistent for minimizing delirium, though guidelines endorse use to shorten duration. Produces lighter sedation, reduces need for benzodiazepines. Reasonable option for appropriately selected patients.
- Hepatic Impairment: Clearance decreases with increasing severity. Consider dose reduction despite titration to effect.
- Pregnancy: No adequate/well-controlled studies. Crosses placenta. Teratogenic effects not observed but adverse effects in rats found. Use only if benefit outweighs potential risks.
- Perioperative/Periprocedural Use: Addressed in separate guidance; operational details determined at facility level.